Scancell Holdings, the AIM-listed developer of novel immunotherapies for the treatment of cancer and infectious disease, has announced that the first patient in the second cohort of the multicentre Phase 1 Modi-1 clinical trial (ModiFY) has been enrolled and dosed.
Modi-1 is the first vaccine based on Scancell’s Moditope platform, while the ModiFY study is a first-in-human clinical trial for patients with triple-negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer.
The dosing follows approval of the dose escalation by the Safety Review Board.
In the trial, Modi-1 will be administered alone or in combination with checkpoint inhibitors (CPIs) in patients with head and neck, triple negative breast and renal tumours.
Chief executive officer Professor Lindy Durrant said: "This is a significant safety milestone for the company, being the first time a citrullinated peptide vaccine from our Moditope® platform has been given to cancer patients.
“We are encouraged that there were no safety concerns in the initial cohort, allowing us to proceed smoothly with the dose escalation."
Scancell expects further safety and immunogenicity data to be available in the second half of 2022, with early efficacy data expected in 2023.
SCLP shares were up 2.4% on the day as of 16:15, August 16.